20 articles
Major study shows CGM users had dramatically lower rates of complications and death compared to traditional monitoring methods.
New study shows CGMs improve blood sugar control and birth outcomes compared to traditional glucose testing during pregnancy.
FDA-integrated CGMs provide superior accuracy and safety compared to non-approved devices flooding global markets.
Machine learning clusters CGM data into four distinct glycemic patterns, each linked to unique diabetic complication risks.
Wearable microneedle patches tap interstitial fluid to monitor glucose, lactate, and electrolytes in real time — no needles, no lab.
Comprehensive review reveals hexokinase method as the most precise technique for glucose testing in clinical laboratories.
Machine learning analyzes glucose patterns to identify distinct metabolic subphenotypes in type 2 diabetes patients.
A rigorous MRI-based study finds that repeated hypoglycemia episodes leave brain glucose transport kinetics unchanged, challenging a leading hypothesis.
Major diabetes organizations call for individualized tech approaches to overcome access barriers and reduce health disparities.
New review exposes stark disparities in diabetes care across Asia-Pacific, from insulin access to advanced technologies like CGM and pumps.
New research reveals hypoglycemia after glucose tolerance tests in some type 2 diabetes patients with higher insulin sensitivity.
Breakthrough modulator therapies are changing how doctors diagnose and treat diabetes in cystic fibrosis patients worldwide.
Study reveals how multiple genes interact to influence blood sugar control in GCK-MODY diabetes, affecting diagnosis timing.
A major Cochrane network meta-analysis protocol will rank all insulin regimens by efficacy and safety for adults with type 1 diabetes.
New study shows fasted morning resistance training produces more consistent glucose responses than fed afternoon sessions.
8-year study of 3,505 Chinese adults shows combining triglyceride-glucose index with waist circumference best predicts cardiovascular disease.
A landmark Lancet review reveals GLP-1 receptor agonists protect the heart, kidneys, liver, and brain — reshaping how we think about metabolic medicine.
Artificial intelligence shows promise for improving diabetes screening and management in resource-limited settings worldwide.
Expert consensus provides updated recommendations for managing popular weight-loss medications before and after surgery.
A 60-week RCT finds semaglutide 2.4 mg sustains ~240 kcal/day reduction even after appetite benefits diminish.
